Biogen Idec (BIIB) 118.74 0.00

Biogen Idec, Inc.
(BIIB) 118.74 0.00

Last Trade:	118.14	Day Range:	118.14 - 118.14
Trade Time:	08:02PM	52wk Range:	65.39 - 123.23
Prev. Close:	118.14	Market Cap:	28.2B
Open:	0.00	Div Yield:	0
Volume:	1900	PE:	230
EPS:	5.04

The Latest On BIIB

Morgan Stanley Initiates Coverage on Biogen Idec at Overweight, Announces PT of $140 2/10/12 6:39am

Benzinga's Top Pre-Market Losers 1/31/12 8:24am

From Earlier: Biogen Idec and Elan Corporation Announce ASCEND Study to Evaluate the Effectiveness of TYSABRI as a Treatment for Secondary-Progressive Multiple Sclerosis 1/26/12 8:53am

Oppenheimer Releases Biogen Idec Company Update 1/23/12 9:43am

Quest Diagnostics STRATIFY JCV First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients 1/20/12 4:00pm

Deutsche Bank Maintains Buy on Biogen Idec After European Medical Agency Announcement 1/20/12 7:11am

Citigroup Maintains Neutral on Biogen Idec After Analyst Meeting 1/11/12 2:12pm

Just What The Doctor Ordered: 4 ETFs For Biotech M&A 1/9/12 3:49pm

Biogen Idec and Isis Pharmaceuticals Announce Global Collaboration for Antisense Program Targeting Spinal Muscular Atrophy 1/4/12 8:31am

Top 4 Large-Cap Stocks In The Biotechnology Industry With The Highest Operating Margin 12/29/11 3:21am

Best Biotech Stocks of 2011 12/27/11 10:39am

Deutsche Bank Reiterates Buy, $129 PT On Biogen Idec 12/20/11 11:18am

Morgan Stanley Initiates Coverage on Biogen Idec at Overweight, Announces PT of $140 2/10/12

Benzinga's Top Pre-Market Losers 1/31/12

From Earlier: Biogen Idec and Elan Corporation Announce ASCEND Study to Evaluate the Effectiveness of TYSABRI as a Treatment for Secondary-Progressive Multiple Sclerosis 1/26/12

Oppenheimer Releases Biogen Idec Company Update 1/23/12

Quest Diagnostics STRATIFY JCV First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients 1/20/12

Deutsche Bank Maintains Buy on Biogen Idec After European Medical Agency Announcement 1/20/12

Citigroup Maintains Neutral on Biogen Idec After Analyst Meeting 1/11/12

Just What The Doctor Ordered: 4 ETFs For Biotech M&A 1/9/12

Biogen Idec and Isis Pharmaceuticals Announce Global Collaboration for Antisense Program Targeting Spinal Muscular Atrophy 1/4/12

Top 4 Large-Cap Stocks In The Biotechnology Industry With The Highest Operating Margin 12/29/11

Best Biotech Stocks of 2011 12/27/11

Deutsche Bank Reiterates Buy, $129 PT On Biogen Idec 12/20/11

Just What The Doctor Ordered: 4 ETFs For Biotech M&A 1/9/12

Top 4 Large-Cap Stocks In The Biotechnology Industry With The Highest Operating Margin 12/29/11

Best Biotech Stocks of 2011 12/27/11

Deutsche Bank Reiterates Buy, $129 PT On Biogen Idec 12/20/11

J.P. Morgan Reiterates Neutral On Biogen Idec 12/6/11

ISI Reiterates Buy, $120 PT On Biogen 12/5/11

Top 4 Large-Cap Stocks In The Biotechnology Industry With The Highest EPS 12/2/11

Idenix and Spectrum Pharmaceuticals to Open Near 52-Week Highs 11/22/11

Financial Breakfast: Morning News Summary for October 28, 2011 10/28/11

Biogen Idec Earnings Preview: Analysts Expect Higher EPS, Revenue 10/25/11

Earnings Expectations for the Week of October 24 10/23/11

Earnings Season Kicks Off 10-17-2011 10/17/11

Morgan Stanley Initiates Coverage on Biogen Idec at Overweight, Announces PT of $140 2/10/12

Oppenheimer Releases Biogen Idec Company Update 1/23/12

Deutsche Bank Maintains Buy on Biogen Idec After European Medical Agency Announcement 1/20/12

Citigroup Maintains Neutral on Biogen Idec After Analyst Meeting 1/11/12

Deutsche Bank Reiterates Buy, $129 PT On Biogen Idec 12/20/11

J.P. Morgan Reiterates Neutral On Biogen Idec 12/6/11

ISI Reiterates Buy, $120 PT On Biogen 12/5/11

Deutsche Bank Maintains Buy Rating and $129 PT on Biogen Idec 11/14/11

JP Morgan Maintains Neutral for Biogen Idec on Positive Lemtrada Data 11/14/11

Financial Breakfast: Morning News Summary for October 28, 2011 10/28/11

Oppenheimer Raises PT on Biogen Idec to $127 from $109, Maintains Outperform 10/26/11

UPDATE: Piper Jaffray Raises PT on Biogen Idec to $135 10/26/11

Trade BIIB
NOW!

Partner Headlines

Betting On Biotech 2/10/12

Research Analyst's New Ratings ( AKS, RKT, ONXX, GILD, CELG, BIIB, BEAV, AVEO, AMGN, IDIX ) 2/10/12

Forget Big Pharma, It's Time For A Biotech ETF - ETF News And Commentary 2/9/12

Forget Big Pharma, It Is Time For A Biotech ETF - ETF News And Commentary 2/9/12

NASDAQ 100 Round Up - Higher: CERN, NVDA, VMED 2/8/12

Uptrend Still Intact, But Buys Get Harder To Find 2/6/12

Biogen Idec Inc Reports Operating Results (10-K) 2/3/12

Gilead Sciences, Alexion Lead Surge In Biotech Stocks 2/3/12

Biogen Idec Inc (BIIB) Executive VP and CFO Paul J Clancy sells 21,400 Shares 2/3/12

How Many Stocks Should You Own? - Investment Ideas 2/3/12

AIDS-Fighter Gilead Misses EPS Views; Shares Dip Late 2/2/12

Press Releases

Biogen Idec to Present at the Leerink Swann Global Healthcare Conference 2/8/12 Business Wire Story

Biogen Idec Surpasses $5 Billion in 2011 Annual Revenue 1/31/12 Business Wire Story

Biogen Idec Appoints Kenneth DiPietro Executive Vice President, Human Resources 1/30/12 Business Wire Story

ASCEND Study to Evaluate the Effectiveness of TYSABRI® (natalizumab) as a Treatment for Secondary-Progressive Multiple Sclerosis 1/27/12 Business Wire Story

FDA Updates TYSABRI® (natalizumab) Label to Include Anti-JC Virus Antibody Status as a PML Risk Factor 1/20/12 Business Wire Story

Quest Diagnostics STRATIFY JCV™ First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients 1/20/12 Newswire Story

Biogen Idec to Report Fourth Quarter & Year End 2011 Financial Results on January 31, 2012 1/13/12 Business Wire Story

RBCC Enters New World of Opportunity 1/13/12 Business Wire Story

Biogen Idec Presents 2012 Strategic Priorities at 30th Annual J.P. Morgan Healthcare Conference 1/9/12 Business Wire Story

RBCC Announces Global Marketing Initiative 1/5/12 Business Wire Story

Biogen Idec and Isis Pharmaceuticals Announce Global Collaboration for Antisense Program Targeting Spinal Muscular Atrophy 1/4/12 Business Wire Story

Biogen Idec to Present at the 30th Annual J.P. Morgan Healthcare Conference 1/3/12 Business Wire Story

Get the latest BIIB stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Biogen Idec, Inc. stock price.

Biogen Idec, Inc. by YCharts

Biogen Idec (BIIB) 118.74 0.00

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On BIIB

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social